Pluvicto demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) in patients with PSMA–positive metastatic castration ...

New report finds colorectal cancer rising among U.S. adults under 55 Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week.

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistant prostate cancer ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

Novartis (NVS) said on Monday that its radioligand therapy Pluvicto (INN: lutetium 177Lu) met the main goal of a phase 3 trial in certain patients with prostate cancer. Read more.

In the final overall survival analysis, researchers pitted Lu-177-PSMA-617 (Pluvicto) against an ARPI in the second-line ...

Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to ...

In the Phase 3 study supporting Pluvicto’s new indication, more than 60% of patients in the ARPI arm went on to receive Novartis’ drug, muddying the survival comparison between the two groups.

Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply to new ...

Novartis got a clinical data boost that could support its radiotherapy Pluvicto ’s $2 billion-plus peak sales ambition. Pluvicto helped patients with previously treated PSMA-positive metastatic ...

Radioligand therapy uses radio-labeled antibodies to deliver targeted radiation directly to prostate cancer cells, minimizing damage to healthy tissue, resulting in fewer and less grueling side ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have ...